Прилепская В. Н. Инновации в контрацепции. Зоэли® – новый комбинированный оральный контрацептив. ФГБУ «Научный Центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» Минздравсоцразвития России. 2012.
Lello S. Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy//Drugs. 2010. № 70. Р. 541–559.
Odlind V., Milsom I., Persson I. et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?//Acta Obstet. Gynecol. Scand. 2002. № 81. Р. 482–490.
Alsina J. C. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives//Eur. J. Contracept. Reprod. Health Care. 2010. Feb. № 15 (1). Р. 1–3.
Basdevant A., Pelissier C., Conard J., Degrelle H., Guyene T. T., Thomas J. L. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women//Contraception. 1991. № 44. Р. 599–605.
Basdevant A., Pelissier C., Conard J., Degrelle H., Guyene T. T., Thomas J. L. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women//Contraception. 1991. № 44. Р. 599–605.
Ruan X., Seeger H., Mueck A. O. The pharmacology of nomegestrol acetate//Maturitas. 2012. № 7. Р. 345–353.
Simoncini T., Caruso A., Garibaldi S. et al. Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate// Obstet. Gynecol. 2006. Oct. № 108 (4). Р. 969–978.
van Hylckama Vlieg A., Helmerhorst F. M., Vandenbroucke J. P. et al. The venous thrombotic risc of oral contraceptives, effects of estrogen dose and progesterone types: results of the MEGA case-control study//BMJ. 2009. № 339. Р. 2921.
Dorangeon P., Thomas J. L., Choisy H., Lumbroso M., Hazard M. C. Effects of nomegestrol acetate on carbohydrate metabolism//Diabete Metab. 1993. № 19. Р. 441–445.
Савельева И. С. Молочные железы и гормональная контрацепция//Гинекология. 2000. № 1. С. 32–51.
Seeger H., Mueck A. O. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data//J. Steroid. Biochem. Mol. Biol. 2008. № 109. Р. 11–15.
Ruan X., Neubauer H., Yang Y. et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells// Climacteric. 2012.
Ruan X., Schneck H., Schultz S. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells // Gynecological Endocrinology. 2012. Early Online. Р. 1–4.
European Medicines Agency. Zoely (nomegestrol/estradiol): European public assessment report [online]. Available from URL: http:// www. ema. europa.eu/docs/en_GB/document_library/EPAR_Public assessment report/human/001213/ WC500115833.pdf [Accessed 2012 Apr 17].http://www
Gaussem P., Alhenc-Gelas M., Thomas J.-L. et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol // Trombosis and Haemostasis. 2011.
Agren U.M., Anttila M., Rantala M.L. et al. Effects of monophasic combined oral contraceptive containing nomegestrole acetate and 17b-estadiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function // Eur. J. Contracept. Reprod. Health Care. 2011. №16. Р. 458–467.